Prognostic importance of glycemic variability on left ventricular reverse remodeling after the first episode of ST-segment elevation myocardial infarction.
Acute myocardial infarction
Continuous glucose monitoring system
Glucose
Glycemic variability
Remodeling
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
04 08 2023
04 08 2023
Historique:
received:
20
04
2023
accepted:
20
07
2023
medline:
7
8
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
This study aimed to investigate the effect of glycemic variability (GV), determined using a continuous glucose monitoring system (CGMS), on left ventricular reverse remodeling (LVRR) after ST-segment elevation myocardial infarction (STEMI). A total of 201 consecutive patients with STEMI who underwent reperfusion therapy within 12 h of onset were enrolled. GV was measured using a CGMS and determined as the mean amplitude of glycemic excursion (MAGE). Left ventricular volumetric parameters were measured using cardiac magnetic resonance imaging (CMRI). LVRR was defined as an absolute decrease in the LV end-systolic volume index of > 10% from 1 week to 7 months after admission. Associations were also examined between GV and LVRR and between LVRR and the incidence of major adverse cardiovascular events (MACE; cardiovascular death, acute coronary syndrome recurrence, non-fatal stroke, and heart failure hospitalization). The prevalence of LVRR was 28% (n = 57). The MAGE was independent predictor of LVRR (odds ratio [OR] 0.98, p = 0.002). Twenty patients experienced MACE during the follow-up period (median, 65 months). The incidence of MACE was lower in patients with LVRR than in those without (2% vs. 13%, p = 0.016). Low GV, determined using a CGMS, was significantly associated with LVRR, which might lead to a good prognosis. Further studies are needed to validate the importance of GV in LVRR in patients with STEMI.
Sections du résumé
BACKGROUND
This study aimed to investigate the effect of glycemic variability (GV), determined using a continuous glucose monitoring system (CGMS), on left ventricular reverse remodeling (LVRR) after ST-segment elevation myocardial infarction (STEMI).
METHODS
A total of 201 consecutive patients with STEMI who underwent reperfusion therapy within 12 h of onset were enrolled. GV was measured using a CGMS and determined as the mean amplitude of glycemic excursion (MAGE). Left ventricular volumetric parameters were measured using cardiac magnetic resonance imaging (CMRI). LVRR was defined as an absolute decrease in the LV end-systolic volume index of > 10% from 1 week to 7 months after admission. Associations were also examined between GV and LVRR and between LVRR and the incidence of major adverse cardiovascular events (MACE; cardiovascular death, acute coronary syndrome recurrence, non-fatal stroke, and heart failure hospitalization).
RESULTS
The prevalence of LVRR was 28% (n = 57). The MAGE was independent predictor of LVRR (odds ratio [OR] 0.98, p = 0.002). Twenty patients experienced MACE during the follow-up period (median, 65 months). The incidence of MACE was lower in patients with LVRR than in those without (2% vs. 13%, p = 0.016).
CONCLUSION
Low GV, determined using a CGMS, was significantly associated with LVRR, which might lead to a good prognosis. Further studies are needed to validate the importance of GV in LVRR in patients with STEMI.
Identifiants
pubmed: 37542320
doi: 10.1186/s12933-023-01931-3
pii: 10.1186/s12933-023-01931-3
pmc: PMC10403862
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, et al. Inflammation as a driver of adverse left ventricular remodeling after Acute myocardial infarction. J Am Coll Cardiol. 2016;67(17):2050–60.
doi: 10.1016/j.jacc.2016.01.073
pubmed: 27126533
Rodriguez-Palomares JF, Gavara J, Ferreira-Gonzalez I, Valente F, Rios C, Rodriguez-Garcia J, et al. Prognostic value of initial left ventricular remodeling in patients with reperfused STEMI. JACC Cardiovasc Imaging. 2019;12(12):2445–56.
doi: 10.1016/j.jcmg.2019.02.025
pubmed: 31202752
Funaro S, La Torre G, Madonna M, Galiuto L, Scara A, Labbadia A, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute myocardial infarction contrast imaging (AMICI) multicenter study. Eur Heart J. 2009;30(5):566–75.
doi: 10.1093/eurheartj/ehn529
pubmed: 19098019
Gohbara M, Iwahashi N, Kataoka S, Hayakawa Y, Sakamaki K, Akiyama E, et al. Glycemic variability determined by continuous glucose monitoring system predicts left ventricular remodeling in patients with a First ST-Segment Elevation myocardial infarction. Circ J. 2015;79(5):1092–9.
doi: 10.1253/circj.CJ-14-1226
pubmed: 25739857
Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol. 2018;17(1):116.
doi: 10.1186/s12933-018-0761-5
pubmed: 30121076
pmcid: 6098663
Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644–55.
doi: 10.2337/diab.19.9.644
pubmed: 5469118
American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):67–74.
doi: 10.2337/dc13-S067
Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol. 2010;55(22):2470–9.
doi: 10.1016/j.jacc.2010.01.049
pubmed: 20510214
Bulluck H, Rosmini S, Abdel-Gadir A, Bhuva AN, Treibel TA, Fontana M, et al. Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction. Sci Rep. 2017;7(1):14676.
doi: 10.1038/s41598-017-15353-1
pubmed: 29116176
pmcid: 5676975
Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74(2):238–56.
doi: 10.1016/j.jacc.2019.05.024
pubmed: 31296297
pmcid: 7363031
Wang X, Zhao X, Dorje T, Yan H, Qian J, Ge J. Glycemic variability predicts cardiovascular complications in acute myocardial infarction patients with type 2 diabetes mellitus. Int J Cardiol. 2014;172(2):498–500.
doi: 10.1016/j.ijcard.2014.01.015
pubmed: 24529823
Okada K, Hibi K, Gohbara M, Kataoka S, Takano K, Akiyama E, et al. Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. Cardiovasc Diabetol. 2015;14:111.
doi: 10.1186/s12933-015-0275-3
pubmed: 26289581
pmcid: 4546046
Kataoka S, Gohbara M, Iwahashi N, Sakamaki K, Nakachi T, Akiyama E, et al. Glycemic variability on continuous glucose monitoring system predicts Rapid Progression of Non-Culprit Lesions in patients with Acute Coronary Syndrome. Circ J. 2015;79(10):2246–54.
doi: 10.1253/circj.CJ-15-0496
pubmed: 26227393
Gohbara M, Hibi K, Mitsuhashi T, Maejima N, Iwahashi N, Kataoka S, et al. Glycemic variability on continuous glucose monitoring system correlates with Non-Culprit Vessel Coronary Plaque vulnerability in patients with First-Episode Acute Coronary syndrome - optical coherence Tomography Study. Circ J. 2016;80(1):202–10.
doi: 10.1253/circj.CJ-15-0790
pubmed: 26511357
Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076–82.
doi: 10.2337/dc12-0199
pubmed: 22688551
pmcid: 3447848
Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014;15(10):18381–406.
doi: 10.3390/ijms151018381
pubmed: 25314300
pmcid: 4227221
Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of Glycemic Indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and Diabetic Complications. J Diabetes Res. 2020;2020:7489795.
doi: 10.1155/2020/7489795
pubmed: 33123598
pmcid: 7585656
Gohbara M, Iwahashi N, Nakahashi H, Kataoka S, Takahashi H, Kirigaya J, et al. Clinical impact of admission urinary 8-hydroxydeoxyguanosine level for predicting cardiovascular mortality in patients with acute coronary syndrome. Heart Vessels. 2021;36(1):38–47.
doi: 10.1007/s00380-020-01663-4
pubmed: 32632553
Shah AK, Bhullar SK, Elimban V, Dhalla NS. Oxidative stress as a mechanism for functional alterations in Cardiac Hypertrophy and Heart failure. Antioxid (Basel). 2021;10(6).
Bugger H, Pfeil K. Mitochondrial ROS in myocardial ischemia reperfusion and remodeling. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165768.
doi: 10.1016/j.bbadis.2020.165768
pubmed: 32173461
Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203–30.
doi: 10.1515/hsz-2013-0241
pubmed: 24127541
Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol. 2020;19(1):102.
doi: 10.1186/s12933-020-01085-6
pubmed: 32622354
pmcid: 7335439
Lee H, Park SE, Kim EY. Glycemic variability impacted by SGLT2 inhibitors and GLP 1 agonists in patients with diabetes Mellitus: a systematic review and Meta-analysis. J Clin Med. 2021;10(18).
von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421–32.
doi: 10.1093/eurheartj/ehac494
Cerasola G, Nardi E, Mule G, Palermo A, Cusimano P, Guarneri M, et al. Left ventricular mass in hypertensive patients with mild-to-moderate reduction of renal function. Nephrol (Carlton). 2010;15(2):203–10.
doi: 10.1111/j.1440-1797.2009.01178.x